Caligan Partners’s SAB Biotherapeutics SABS Stock Holding History

Caligan Partners’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.1M	Hold	7,967,207	–	–	1.46%	15
2026 Q1	$30.5M	Buy	+7,967,207	New	+$31.8M	2.03%	15

Other funds holding SABS

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Caligan Partners's SABS Position: Q2 2026 in Review

Caligan Partners held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 7,967,207 shares worth $31.1M. The position accounts for 1.46% of the portfolio, ranked #15.

Caligan Partners first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Caligan Partners held 7,967,207 shares of SAB Biotherapeutics worth $31.1M as of Q2 2026.
Caligan Partners left its SAB Biotherapeutics share count unchanged in Q2 2026.
SAB Biotherapeutics made up 1.46% of Caligan Partners's portfolio in Q2 2026, its #15 holding.
Caligan Partners first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.